| Literature DB >> 16871495 |
Peter D Hanson1, Kenneth C Brooks, Jerry Case, Michael Conzemius, Wanda Gordon, James Schuessler, Bert Shelley, Roger Sifferman, Marlene Drag, Roberto Alva, Laura Bell, Davida Romano, Candis Fleishman.
Abstract
A total of 249 client-owned dogs with osteoarthritis were treated with firocoxib (5 mg/kg/day) or a positive control, etodolac (10-15 mg/kg/day), for 30 days. Veterinary examinations were performed on approximately days 0 (visit 1), 14 (visit 2), and 29 (visit 3). Based on defined noninferiority criteria, firocoxib and etodolac were comparable. Based on the magnitude of the change from baseline, improvement with firocoxib was significantly greater than with etodolac for lameness at a trot (visits 2 and 3) and for lameness at a walk, pain on manipulation, and range of motion (visit 3) (P < .05). In weekly owner evaluations, firocoxib provided significantly greater improvement than etodolac (P < .05) at each scoring.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16871495
Source DB: PubMed Journal: Vet Ther ISSN： 1528-3593